ROCHE HD DRUG TRIAL ANNOUNCED FOR SYDNEY

The Huntington Disease Service at Westmead Hospital has been approved to participate in a new drug trial, called Generation HD1. This study tests a Huntingtin-lowering (also known as gene silencing) agent developed by IONIS, and the trial will be run by a company called Roche. The study involves lumbar punctures, MRI scans, assessments and questionnaires.


The main goal of Generation HD1 is to compare the effects, good and/or bad, of RO7234292 against placebo, in study participants with HD. Participants must be between the ages of 25-65, have early stage Huntington Disease, and meet additional criteria. It is expected the study will involve 660 people with HD worldwide.


If you would like more information, you can call Westmead on 0456 740 612. The phone will be monitored on Mondays and Thursdays. Please leave a message if we cannot answer when you call.


Huntington’s NSW & ACT, and the Huntington Disease Service at Westmead will continue to provide updates on HD research through the Huntington’s NSW&ACT website.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.